Navigation Links
WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of Osteologix
Date:9/6/2007

NEW YORK, Sept. 6 /PRNewswire/ -- Philip Young, Chief Executive Officer of Osteologix, Inc. (OTC Bulletin Board: OLGX) (http://www.osteologix.com) will be featured in an exclusive interview with http://www.wallst.net that is scheduled to take place on September 6 at 11 a.m. EDT. The interview will be posted on http://www.wallst.net by 8 p.m. EDT on September 6.

The interview will cover topics including Osteologix's market potential, growth initiatives, competitive positioning, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window on the right-hand column of the "Interviews" section once it is posted.

About Osteologix:

Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix is developing NB S101, a once daily tablet containing strontium malonate, as a treatment for osteoporosis. The phase II study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial with the objective of assessing the effects of NB S101 on bone metabolism while also evaluating its safety, tolerability and pharmacokinetics in postmenopausal women. In addition to the primary endpoint of bone resorption, the company is evaluating the effects of NB S101 on bone formation and bone mineral density.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site. Financial Filings Corp. is expecting to receive two hundred eighty dollars from Osteologix, Inc. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)

Contact: WallSt.net

800-4-WALL-ST


'/>"/>
SOURCE Financial Filings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... (PRWEB) , ... January 12, ... ... disposable devices with short response times capable of performing routine electrochemical biosensing ... disposable screen-printed electrodes provide fast, sensitive detection and quantification of various analytes ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
(Date:1/11/2017)... AURORA, Colo. (PRWEB) , ... January 11, 2017 ... ... in the journal Clinical Cancer Research show early promise of the investigational anti-cancer ... progressed despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily ...
(Date:1/11/2017)... 11, 2017  Brian Mehling, M.D., world-renowned stem cell ... Horizon International (BHI), will be attending the 47th Annual ... from January 17-20, 2017. This will be Dr. ... The theme of this year,s forum is Responsive and ... will address strategies for fostering greater social inclusion and ...
Breaking Biology Technology:
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
Breaking Biology News(10 mins):